TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07732309: A Phase I, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of ATG-201 in Adult Participants With Autoimmune Diseases

Sponsor: Antengene Biologics Limited · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 149 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$3,894,360

Rescue Site Savings

+$2,580,600

Unlock Full NCT07732309 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07732309 Rescue Dossier →